References
Colorectal Cancer Screening and Surveillance—American Family Physician. Accessed March 11, 2015. http://www.aafp.org/afp/2015/0115/p93.html.
Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–50. doi:10.1016/j.ejca.2003.12.004.
Van Kuilenburg ABP, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G> a mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids. 2008;27(6–7):692–8. doi:10.1080/15257770802145009.
Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4(3):181–9. doi:10.3816/CCC.2004.n.018.
Blasco H, Boisdron-Celle M, Bougnoux P, Gilles C, Tournamille J-F, Ciccolini J, et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol. 2008;65(6):966–70. doi:10.1111/j.1365-2125.2008.03106.x.
Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer J-C, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272–5. doi:10.1007/s00280-005-0139-8.
Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104(1):1–9. doi:10.1007/PL00008711.
Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288–96. doi:10.3816/CCC.2006.n.047.
van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705–12.
Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271–82. doi:10.1016/j.canlet.2006.09.006.
Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D’Amico M, et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355–61. doi:10.1007/s00280-011-1709-6.
Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer J-C, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678–85. doi:10.1097/01.ftd.0000245771.82720.c7.
National Guideline Clearinghouse/Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Accessed March 11, 2015. http://www.guideline.gov/content.aspx?id=47994.
Magnani E, Farnetti E, Davide N, Casali B, Savoldi L, Focaccetti C, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417–23. doi:10.1007/s11739-013-0936-8.
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2015. doi:10.1200/JCO.2015.63.1325.
Barni S, Ghidini A, Coinu A, Borgonovo K, Petrelli F. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs. 2014;25(10):1122–8. doi:10.1097/CAD.0000000000000133. Review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Kodali, S., Bathini, V., Rava, P. et al. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. J Gastrointest Canc 48, 66–69 (2017). https://doi.org/10.1007/s12029-015-9797-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-015-9797-x